RESUMEN
Intra-arterial chemotherapy (IAC) is an interventional treatment for retinoblastoma (RB) which infuses the chemotherapeutic agents through ophthalmic artery using microcatheters to control the tumor.Compared with systemic chemotherapy,IAC could significantly increase the globe salvage of advanced and recurrent RB without serious adverse event.Due to the absence of systemic absorption after IAC,no longer effectively kill tumor cell,which have potential danger to leads to inadequate elimination extraocular tumor cells.The most common systemic complications following IAC is myelosuppression;local ocular toxicities include eyelid edema,delacrimation,blepharoptosis,vitreous hemorrhage,retinal artery obstruction.During the last 10 years of clinical application,IAC become one of first-line treatment for intraocular RB.However,at present,there is still a lack of randomized controlled multicenter studies and long-term follow up of IAC.
RESUMEN
Retinoblastoma (RB) is the most common intraocular malignant tumor in children. With advanced clinical technologies there are more and more methods available to treat retinoblastoma, and make it is possible to delivery individualized protocol combined traditional treatments with modern regimen to patients now. In order to improve the survival rate and the life quality of RB patients in China, it is very important to make a suitable system of standardized therapy based on results from developed countries and health policies of our own country.
RESUMEN
Treatment options of retinoblastoma should be individualized. Patients with early intraocular stage may be managed with focal treatments, including cryotherapy, thermotherapy, laser photocoagulation, brachytherapy and so on. Patients with middle in- traocular stage may be treated with chemoreduction plus focal therapy. In patients with advanced stage, enucleation and chemotherapy are recommended, with the addition of orbital radiation for patients with extraocular retinoblastoma. Patients with systemic metastases require intensive chemotherapy and consolidation with autologous hematopoietic stem cell rescue.